Vivoryon Therapeutics (VVY) Q3 2026 earnings summary

Executive summary

• Priority is securing funding or a partnership for varoglutamstat’s planned Phase 2b study in advanced diabetic kidney disease (DKD); alternative strategic options are also under review.

• Rights to varoglutamstat in Greater China returned from Simcere, consolidating global rights and supporting a kidney-disease focus.

Financial highlights

• Nine-month revenue was €0, unchanged YoY; net loss narrowed to €4.8 million from €7.6 million.

• R&D expense fell to €2.3 million from €3.7 million, mainly on €1.0 million lower kidney-related clinical development and analysis costs.

• G&A expense declined to €2.7 million from €4.0 million, reflecting lower share-based personnel costs and cost-saving measures.

• Cash and cash equivalents were €1.7 million at September 30, 2026, versus €5.6 million at December 31, 2025.

Outlook and guidance

• Updated cash runway extends into the second half of December 2026, subject to unforeseen circumstances and excluding SEPA proceeds and other potential financing.

• Phase 2b DKD study initiation and future studies depend on additional funding and/or a partnership.